Efficacy, Safety and Pharmacokinetics of DTG with RIF

NCT03731559 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

200

Enrollment

OTHER

Sponsor class

Conditions

HIV/TB Coinfection

Interventions

DRUG: DTG 50 mg OD with food
DRUG: DTG 50 mg BID

Sponsor

The HIV Netherlands Australia Thailand Research Collaboration

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]